The UK has launched a refreshed Innovative Licensing and Access Pathway (ILAP) to expedite the delivery of transformative medicines to patients in the NHS. This pathway, unique globally, allows medicine developers to collaborate with the national health system, regulators, and health technology assessment bodies from early clinical development stages. Key improvements include NHS involvement, better bespoke services, predictable timelines, early patient interaction, and support for drug-device combinations. The ILAP aims to address unmet clinical needs swiftly while maintaining safety, quality, and effectiveness. The pathway will be refined iteratively based on feedback and evolving life sciences.

#MHRA #NHS #ILAP #Innovative #Licensing #AccessPathway